Decision Impact Trial of the ExoDx Prostate (IntelliScore)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 2/17/2019 |
| Start Date: | July 19, 2017 |
| End Date: | December 29, 2019 |
A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.
The purpose of this research study is to investigate the utility of a validated urine test
which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.
which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.
Primary Objective(s)
1. Evaluate performance of the ExoDx Prostate(IntelliScore) (EPI) to reduce the number of
initial prostate biopsies by greater than or equal to 15% for men with an elevated
Prostate-Specific Antigen 2-10ng/mL presenting for a biopsy in consultation with their
urologist.
2. Compare performance of both the ExoDx Prostate(IntelliScore) 15.6 and 20 cut-points with
respect to the biopsy decision process.
3. Assess physician satisfaction with the ExoDx Prostate(IntelliScore) report including
test result presentation, graphics and interpretation.
4. Assess urologist / patient satisfaction for ease of understanding test results and role
on biopsy decision process.
Secondary Objectives
1. Determine the medical economic impact of the ExoDx Prostate(IntelliScore) test in the
prostate biopsy decision process.
2. Correlation of the ExoDx Prostate(IntelliScore) score with the actual biopsy result by
utilizing the Receiver Operating Characteristic of the Area Under Curve for
discriminating high-grade (greater than or equal to Gleason Score 7, International
Society of Urological Pathology 2 and 3) from low-grade (Gleason Score 6, International
Society of Urological Pathology 1) and benign disease on initial prostate needle biopsy.
1. Evaluate performance of the ExoDx Prostate(IntelliScore) (EPI) to reduce the number of
initial prostate biopsies by greater than or equal to 15% for men with an elevated
Prostate-Specific Antigen 2-10ng/mL presenting for a biopsy in consultation with their
urologist.
2. Compare performance of both the ExoDx Prostate(IntelliScore) 15.6 and 20 cut-points with
respect to the biopsy decision process.
3. Assess physician satisfaction with the ExoDx Prostate(IntelliScore) report including
test result presentation, graphics and interpretation.
4. Assess urologist / patient satisfaction for ease of understanding test results and role
on biopsy decision process.
Secondary Objectives
1. Determine the medical economic impact of the ExoDx Prostate(IntelliScore) test in the
prostate biopsy decision process.
2. Correlation of the ExoDx Prostate(IntelliScore) score with the actual biopsy result by
utilizing the Receiver Operating Characteristic of the Area Under Curve for
discriminating high-grade (greater than or equal to Gleason Score 7, International
Society of Urological Pathology 2 and 3) from low-grade (Gleason Score 6, International
Society of Urological Pathology 1) and benign disease on initial prostate needle biopsy.
Inclusion Criteria:
- 50 years of age
- Clinical suspicion for prostate cancer
- Elevated Prostate-specific antigen between: 2.0 - 10 ng/ mL
- No clinical history of a prior negative biopsy
Exclusion Criteria:
- History of prior prostate biopsy.
- Use of medications or hormones that are known to affect serum Prostate-specific
antigen levels within 3-6 months of study enrollment.
- Clinical symptoms of urinary tract infection (including prostatitis) at the time of
enrollment.
- History of prostate cancer.
- History of invasive treatments for benign prostatic hypertrophy (Benign Prostatic
Hyperplasia) or lower urinary track symptoms within 6 months of study enrollment.
- Known hepatitis (all types) and/or HIV documented in patient's medical record.
- Patients with history of concurrent renal/bladder tumors.
We found this trial at
1
site
Towson, Maryland 21204
Principal Investigator: Ronald F Tutrone, MD
Phone: 443-471-5750
Click here to add this to my saved trials
